skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Tesevatinib (Code C62496)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tesevatinib

Definition: An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.

Display Name: Tesevatinib

Label: Tesevatinib

NCI Thesaurus Code: C62496 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1541356  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)-
EXEL 7647
KD 019

External Source Codes: 
CAS Registry Number 781613-23-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 386183
PDQ Open Trial Search ID 386183 (check for NCI PDQ open clinical trial info)
PubMedID Primary Reference 22011666 (see PubMed Primary Reference info)
UMLS CUI C1541356

Other Properties:
     Name Value (qualifiers indented underneath)
code C62496
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name XL647
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom